Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib in Patients With IPMN
NCT00198081Phase 2Terminated
- Sponsor
- Indiana University School of Medicine
- Start
- Sep 2005
- Primary completion
- Apr 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of celecoxib in intraductal papillary mucinous neoplasm (IPMN) (2 arms), sponsored by Indiana University School of Medicine. Primary endpoints: Concentration of PGE2 in Urine at 6 months, Concentration of PGE2 in Serum at 6 months and 2 more. Started Sep 2005; status: terminated.
02
Drugs
celecoxib
03
Conditions
intraductal papillary mucinous neoplasm (IPMN)
Beyond the preview
Go deeper on NCT00198081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00198081.